Form 4: AEON Biopharma CEO Marc Forth Acquires Shares and Options in Recent Transaction
SEC Form 4 Filing
CEO Marc Forth reports acquisition of shares and options in AEON Biopharma, including restricted stock units and stock options, according to a Form 4 filing.
Summary
- Marc Forth, CEO of AEON Biopharma, filed a Form 4 detailing changes in beneficial ownership.
- The filing reports the acquisition of 470,692 shares of Class A Common Stock at $0 on August 31, 2024, through an award of restricted stock units (RSUs) that vest on the second anniversary of the grant date.
- Forth also acquired 1,256,062 stock options on August 31, 2024, exercisable in monthly installments over 18 months, with an exercise price of $0.83.
- The filing corrects a previous error, reclassifying 279,855 RSUs granted on April 26, 2023, from derivative securities to common stock.
- Following these transactions, Forth beneficially owns 750,547 shares of Class A Common Stock and 1,256,062 stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing detailing insider transactions. The acquisition of shares and options by the CEO is a potentially positive sign, but the filing itself is simply a disclosure.
Positives
- The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.
- The vesting schedules for the RSUs and stock options incentivize the CEO to remain with the company and drive long-term value.
Risks
- The vesting of the RSUs and stock options is contingent upon the CEO's continued service, creating a potential risk if the CEO were to leave the company before the vesting dates.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the CEO.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Stakeholder Impact
- Shareholders may view the CEO's increased stake in the company positively.
- Employees may see the CEO's actions as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| April 26, 2023 | Grant date of 279,855 restricted stock units (RSUs) that were previously misreported. |
| July 24, 2023 | Date when the RSUs granted on April 26, 2023, were previously reported as derivative securities due to a clerical error. |
| August 31, 2024 | Date of the reported transactions, including the grant of 470,692 restricted stock units and 1,256,062 stock options. |
| August 30, 2034 | Expiration date of the stock options granted on August 31, 2024. |
| September 04, 2024 | Date of the Form 4 filing. |
Keywords
Form 4, beneficial ownership, stock options, restricted stock units, AEON Biopharma, Marc Forth, CEO, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.